| ²é¿´: 1868 | »Ø¸´: 12 | ||||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||||
[½»Á÷]
¼±Çó·Ò룡£¡£¡£¡£¡ººÒëÓ¢£¡£¡£¡£¡ÔÚÏߵȣ¡£¡£¡£¡
|
||||
|
±¾ÎÄÔÚ×ÛÊöËûÍ¡ÀàÒ©ÎһÀà¶ÔôǼ×Îì¶þõ£¸¨Ã¸A»¹ÔøÒÖÖÆ¼Á£©µÄÒ©Àí×÷ÓúÍÁÙ´²Ó¦Óã¬ÒÔ¼°ÆäÖÐÒ»¸öÖØÒª³ÉÔ±Âå·¥ËûÍ¡µÄÒ©ÀíÑо¿½øÕ¹¡¢Éú²úÏÖ×´µÈµÄ»ù´¡ÉÏ£¬ÈÏΪÂå·¥ËûÍ¡µÄÊг¡ÐèÇóÁ¿»¹ºÜ´ó£¬ÉõÖÁǰ¾°½«¸üºÃ¡£ µ«¼¼Êõ·¢Õ¹Ê¹Éç»á¶ÔÒ½Ò©²úÆ·ÖÊÁ¿ÒªÇóÔ½À´Ô½¸ß£¬ÃÀ¹úÒ©µäÒªÇóÂå·¥ËûÍ¡²úÆ·ÖÐÔÓÖÊ×ܺ¬Á¿²»³¬¹ý1.0%£¬µ¥ÔÓÖʺ¬Á¿²»³¬¹ý0.2%£¬³ý·ÇÄÜÓгä·ÖµÄÒ©ÀíÊý¾ÝÖ¤Ã÷ÔÓÖʳɷֵÄÒ©Àí×÷ÓÃÓëÖ÷³É·ÖÒ»Ö£¬¶øÇÒ²»¾ßÓÐÆäËûµÄ¶¾Àí×÷Óá£ÎÒ¹úÊÇÂå·¥ËûÍ¡ÔÁÏÒ©µÄÖ÷ÒªÉú²ú¹ú£¬ÎªÁËÊÊÓ¦¸÷¹úÒ©µä¶ÔÂå·¥Ëû͡ҩƷµÄÐÂÒªÇó£¬ÓбØÒª¶ÔÂå·¥ËûÍ¡²úÆ·ÖеÄÔÓÖʽøÐÐÉîÈëÑо¿¡£Ê×Ïȵõ½µ¥Ì廯ºÏÎ¼ø¶¨ËüÃǵĽṹ£¬Ã÷È·ËüÃǵÄÐÔÖÊ£¬È»ºó²ûÃ÷ÕâЩÔÓÖʳɷÖÊÇÔÚÉú²úµÄÄÄÒ»»·½Ú²úÉúµÄ£¬ÈçºÎ¼õÉÙËüÃǵIJúÉú£¬ÔÚ´¿»¯¹ý³ÌÖÐÈçºÎ³ýÈ¥ËüÃÇ£»Í¬Ê±ÀÛ»ý×ã¹»µÄÔÓÖʵ¥Ì廯ºÏÎ½øÐÐÒ©ÀíºÍ¶¾ÀíÑо¿¡£ ±¾ÎĵÄÖ÷ÒªÑо¿ÄÚÈݾÍÊǶÔÂå·¥ËûÍ¡·¢½Í²úÎïµÄÔÓÖʳɷֽøÐÐÁË·ÖÀë´¿»¯£¬²¢¼ø¶¨ËüÃǵĽṹ¡£±¾ÎÄÒÔÂå·¥ËûÍ¡ÌáÈ¡´¿»¯×îºó²½ÖèµÄ½á¾§Ä¸ÒºÎªÔÁÏ£¬·´¸´Ó¦Óù轺ÖùÉ«Æ×¡¢¹è½ºÖƱ¸TLC¡¢·´Ïà¹è½ºÖùÉ«Æ×¡¢°ëÖÆ±¸HPLCµÈ·½·¨£¬´ÓÖзÖÀëµÃµ½6¸öÔÓÖʵ¥Ì廯ºÏÎ×ÛºÏÔËÓò¨Æ×ѧ·½·¨£¬ÈçFT-IR¡¢1H-NMR¡¢13C-NMR¡¢1H-1H COSY¡¢HSQC¡¢HMBCºÍMSµÈ£¬¼ø¶¨ÁËËüÃǵĽṹ¡£ÕâЩ»¯ºÏÎï·Ö±ðÊÇ£º |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
¾«Æ··Ò뼯½õ |
» ²ÂÄãϲ»¶
290Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
326Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
¶«ÄÏ´óѧ364Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085600²ÄÁÏÓ뻯¹¤ Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
Ò»Ö¾Ô¸985£¬±¾¿Æ211£¬0817»¯Ñ§¹¤³ÌÓë¼¼Êõ319Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
0703»¯Ñ§µ÷¼Á 290·ÖÓпÆÑоÀú£¬ÂÛÎÄÔÚͶ
ÒѾÓÐ4È˻ظ´
»¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
±¾ÈË¿¼085602 »¯Ñ§¹¤³Ì ר˶
ÒѾÓÐ9È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÎïÀíѧ µ÷¼Á
+1/86
ÕÐÊÕµ÷¼ÁÉú£¬¶¯Îïҽѧ¡¢Ë®²úÑøÖ³¡¢Ë®²ú¶¯ÎïҽѧµÈרҵ
+1/81
¹þ¹¤´ó±¾²¿-µç»¯Ñ§ÐÂÄÜÔ´·½Ïò²©Ê¿¼ñ©Ãû¶î
+1/78
º£ÄÏ´óѧФÓÀê»ÀÏʦÍŶÓÕÐÊÕ2026Ä격ʿÑо¿Éú£¨µÚ¶þÅú£©
+5/40
ÉúֳҽѧÓë×Ó´ú½¡¿µÈ«¹úÖØµãʵÑéÊÒÒÅ´«Ñ§¿ÎÌâ×éÕÐÊÕÑо¿Éú(³¤ÆÚÓÐЧ)
+1/34
·ÄÖ¯¿ÆÑ§Ó빤³Ì¡¢²ÄÁÏ»¯¹¤·½ÏòÕÐÊÕÑо¿Éú
+1/29
³ÏƸÖúÀíÑо¿Ô± - ÎïÀí/²ÄÁÏ/»úеÏà¹Ø×¨Òµ²©Ê¿
+2/20
±±¾©Ä³Ñо¿ÔºÉúÎﻯѧÓë·Ö×ÓÉúÎïѧÏà¹Ø×¨ÒµÉêÇ뿼ºËÖÆ²©Ê¿ÕÐÉú£¨´º¼¾£©
+1/17
ҽѧ327·Öר˶µ÷¼Á
+1/16
¸£½¨Ê¦·¶´óѧ»¯Ñ§Óë²ÄÁÏѧԺ¶Å¿ËîÈÍŶӲ©Ê¿/˶ʿÕÐÉú
+1/15
ɽ¶«Ê¡Ö²Îï»ùµ°°×¼¼Êõ´´ÐÂÖÐÐÄ¿ÎÌâ×éÁªºÏÅàÑøË¶Ê¿Ñо¿ÉúÕÐļÆôÊÂ
+1/13
ÄϾ©Ò½¿Æ´óѧ-Ĥµ°°×½á¹¹Ó빦ÄÜ¿ÎÌâ×é-ÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú
+1/13
Çൺ¿Æ¼¼´óѧ0860 Ò»Ö¾Ô¸./µ÷¼Á ÕÐÉú
+1/9
¹þ¶û±õÀí¹¤´óѧ²ÄÁÏÓ뻯ѧ¹¤³ÌѧԺ ÄÉÃ×¹¦ÄܲÄÁÏÓë¹âµç´ß»¯ÍÅ¶Ó ÕÐÊÕ˶ʿÑо¿Éú
+1/7
½ÌÓý²¿³¤½Ñ§Õߺʹ´ÐÂÍŶӷ¢Õ¹¼Æ»®¡±ÈëÑ¡ÍŶÓÕÐÊÕ ²ÄÁÏ£¬»¯Ñ§Ó뻯¹¤²©Ê¿Ñо¿Éú
+1/7
ÖйúÃñº½·ÉÐÐѧԺÏȽøÁ¬½ÓÍŶÓÕÐÊÕº½¿ÕÓ¡¢º½¿Õ»úеרҵ˶ʿÑо¿Éú£¨Ñ§Ë¶×¨Ë¶¾ù¿É£©
+1/7
¡¾µÚÈýÂÖÕÐÉú£¬31ºÅ½ØÖ¹¡¿°Ä¿Æ´ó³ÏÕÐ2026ÇïÈ«½±²©Ê¿Ñо¿Éú£¨ÄÉÃ×ҽѧ/ÉúÎï²ÄÁÏ·½Ïò£©
+1/6
ÖØÇì´óÑ§Ò©Ñ§ÔºãÆº£Áú¿ÎÌâ×éÄâÕÐÊÕ2026ÄêÉêÇ뿼ºËÖÆ²©Ê¿Ñо¿Éú
+1/5
±±¾©¸ßУ¸±Ð£³¤ÍŶÓÕÐÊÕ»úеÀ࣬»·¾³Ààѧ˶ºÍר˶
+1/5
2026ÄêÕã½Ç廪³¤Èý½ÇÑо¿ÔºÖÇ»ÛÄÜÔ´ÖÐÐÄÕÐÆ¸²©Ê¿ºó-µçÆø·½Ïò
+1/1
Mally89
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 79
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ¹ó±ö: 1.257
- ½ð±Ò: 5347.3
- Ìû×Ó: 3712
- ÔÚÏß: 1225.5Сʱ
- ³æºÅ: 1150928
À¶Ìì306(½ð±Ò+1, ·ÒëEPI+1): ºÇºÇ£¬°ïæ·ÒëÏ£¿ 2011-04-07 11:23:00
ringzhu(·ÒëEPI-1): ¡¡ 2011-04-07 11:24:01
ringzhu(·ÒëEPI-1): ¡¡ 2011-04-07 11:24:01
ÍÛ£¡~ºÃÓÕÈ˰¡£¡~ |
2Â¥2011-04-07 11:15:58
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
3Â¥2011-04-07 11:24:49
5Â¥2011-04-07 11:54:27
6Â¥2011-04-07 12:07:46
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
7Â¥2011-04-07 12:08:30
8Â¥2011-04-07 12:30:11
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
9Â¥2011-04-07 12:31:36
10Â¥2011-04-07 12:32:38
ringzhu
ľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 24
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ¹ó±ö: 1.318
- ½ð±Ò: 1370.6
- Ìû×Ó: 4511
- ÔÚÏß: 703.5Сʱ
- ³æºÅ: 825134
À¶Ìì306(½ð±Ò+149, ·ÒëEPI+1): ·Ç³£¸Ðл£¡£¡£¡£¡ 2011-04-07 12:56:19
|
This article is a review on the pharmacological effects and clinical applications of statins (reductase inhibitors of hydroxymethyl coenzyme A ). based on the pharmacology and production status of lovastatin-one of the important member of statins, there is a great market demand, and even better prospects. The development of technology put a higher standard on the pharmaceutical products. USP has the requirement that unless there are enough evidences to prove that the impurity has the same pharmacological effects as the principal component, and still the impurity has no toxicological effects, the total content of impurities in the product should be less than 1.0%. Single impurity content should be less than 0.2%. China is the major producer of raw materials of lovastatin. In order to meet the new national pharmacopoeia requirements of lovastatin, there is a need to conduct in-depth study of impurities in lovastatin. First of all, compounds are obtained and their structures should be identified, and their properties are studied. And then make clear in reaction steps these impurities are generated. Another problem is how to reduce the production of the impurities,and how to remove them. At the same time, get enough monomer impurity in the compounds to conduct pharmacological and toxicological studies. The main idea of this paper is purification of the impurity in the fermentation products of lovastatin and identification of their structure. In this study the raw materials is the crystal liquor of lovastatin in the final step of extraction and purification. And then take measures like silica gel column chromatography, silica gel prepared by TLC, RP-silica gel column chromatography, semi-preparative HPLC and other methods to get 6 isolated compounds. And Comprehensive usage of spectrum study methods, such as FT-IR, 1H-NMR, 13C-NMR, 1H-1H COSY, HSQC, HMBC and MS can be taken to identify their structures. These compounds are: [ Last edited by ringzhu on 2011-4-7 at 12:49 ] |
11Â¥2011-04-07 12:41:05
12Â¥2011-04-07 12:54:37
¹Å¿É¤×
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
- ·ÒëEPI: 323
- Ó¦Öú: 91 (³õÖÐÉú)
- ¹ó±ö: 16.835
- ½ð±Ò: 19237.1
- Ìû×Ó: 25406
- ÔÚÏß: 1082.3Сʱ
- ³æºÅ: 1034379
13Â¥2011-09-04 18:02:22
¼òµ¥»Ø¸´
Mally894Â¥
2011-04-07 11:28
»Ø¸´














»Ø¸´´ËÂ¥
¸££¡